Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KIR-mismatched haploidentical bone marrow transplantation for multiple myeloma
NL-OMON41842Phase 2Active, not recruiting
- Sponsor
- Maastricht University Medical Center+
- Start
- Apr 2016
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Haploidentical Bone Marrow Transplantation in multiple myeloma (MM), sponsored by Maastricht University Medical Center+. Primary endpoint: Progression-free survival. Started Apr 2016; status: active, not recruiting.
02
Drugs
Haploidentical Bone Marrow Transplantation
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NL-OMON41842.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON41842.